The invention concerns quinazoline derivatives of the formula I
1
wherein X
1
is a direct link or a group such as CO, C(R
2
)
2
and CH(OR
2
);
wherein Q
1
is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q
1
optionally bears up to 3 substituents;
wherein m is 1 or 2 and each R
1
may be a group such as hydrogen, halogeno and trifluoromethyl; and
wherein Q
2
may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q
2
optionally bears up to 3 substituents;
or a pharmaceutically-acceptable salt thereof;
processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.
本发明涉及公式I1的
喹唑啉衍
生物,其中X1是直接连接或类似于CO,C(R2)2和CH(OR2)的基团;其中Q1是苯基,
萘基或5-或6-成员的杂环芳基残基,Q1最多可带有3个取代基;其中m为1或2,每个R1可以是氢,卤代和三
氟甲基等基团;而Q2可以是苯基或9-或10-成员的双环杂环芳基残基,Q2最多可带有3个取代基;或其药学上可接受的盐;制备它们的方法,包含它们的制药组合物和利用它们的受体
酪氨酸激酶抑制性质治疗增生性疾病,如癌症。